National Psoriasis Foundation launches online patient-centered research network

July 24, 2015

PORTLAND, Oregon (July 24, 2015)--For the first time, people with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation's (NPF) patient-centered research network called Citizen Pscientist.

An online, interactive community, Citizen Pscientist allows people living with psoriatic disease to connect with researchers, share their data and get input from others in the community, and ultimately drive the direction of psoriatic disease research. Learn more at

The platform unites psoriatic disease patients from around the country to contribute their own data about triggers, treatments, associated health conditions and lifestyle factors related to psoriasis and psoriatic arthritis. As Citizen Pscientists, the group serves as both the subject and the scientist by exploring data presented by others in the community, forming their own hypotheses and questions, and analyzing the data through visualization tools.

"The National Psoriasis Foundation puts people living with psoriatic disease at the center of everything we do. This platform is our latest effort to bring patients to the table when we create our research agenda," said Michael Siegel, Ph.D., National Psoriasis Foundation director of research. "Citizen Pscientist will help bridge the gaps between researchers studying psoriasis and psoriatic arthritis and the people living with these conditions."

The patients will connect with seven of the nation's top psoriatic disease researchers who serve as advisors to share their hypotheses and questions.

"We hope to fund a future Psoriasis Foundation research grant with information from our Citizen Pscientist community," added Siegel.

The platform launched today builds on a pilot program developed in 2013. In this next phase, the Psoriasis Foundation also aims to use the Citizen Pscientist data to identify a future comparative effectiveness research project. It will likely compare multiple psoriatic disease interventions based on what patients think is most important. Additionally, information provided to Citizen Pscientist will form a registry of anonymous patient data that can be explored by researchers to better understand psoriatic disease.
This project was funded through a Patient-Centered Outcomes Research Institute (PCORI) Pipeline-to-Proposal Award, administered on behalf of PCORI by the Colorado Foundation for Public Health and the Environment.

Become a Citizen Pscientist today at

About the National Psoriasis Foundation

National Psoriasis Foundation (NPF) is the world's largest nonprofit dedicated to people with psoriasis and psoriatic arthritis. Our priority is to provide the services people need to take control of their condition, while increasing research to find a cure. In addition to serving more than 2.1 million people annually through our health education and advocacy initiatives, NPF has funded more than $11 million in research grants and fellowships. Learn more about the Psoriasis Foundation at or call 800-723-9166. Follow us on Facebook and Twitter.

National Psoriasis Foundation

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to